CORRELATION OF THE INSULIN RECEPTOR EXPRESSION AND THE RESISTANCE TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN ADVANCED CLEAR CELL RENAL CELL CARCINOMA

被引：0
|
作者：
Takahashi, Masayuki
Daizumoto, Kei
Fukuhara, Yayoi
Ozaki, Keisuke
Tsuda, Megumi
Kusuhara, Yoshito
Mori, Hidehisa
Fukawa, Tomoya
Yamamoto, Yasuyo
Yamaguchi, Kunihisa
Fukumori, Tomoharu
Kanayama, Hiroomi
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP72-06
引用
收藏
页码：E954 / E954
页数：1
相关论文
共 50 条
  • [41] Molecular predictors of response and survival outcomes in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGFTKis)
    Agarwal, Neeraj
    Janakiraman, Manickam
    Albertson, Dan
    Guttapalli, Asha
    Gowrishankar, Banumathy
    Merriman, Joseph
    Gill, David
    Thodima, Venkata
    Kamalakaran, Sitharthan
    Stenehjem, David
    Houldsworth, Jane
    BJU INTERNATIONAL, 2015, 116 : 1 - 1
  • [42] Insulin Receptor Expression in Clear Cell Renal Cell Carcinoma and Its Relation to Prognosis
    Lkhagvadorj, Sayamaa
    Oh, Sung Soo
    Lee, Mi-Ra
    Jung, Jae Hung
    Chung, Hyun Chul
    Cha, Seung-Kuy
    Eom, Minseob
    YONSEI MEDICAL JOURNAL, 2014, 55 (04) : 861 - 870
  • [43] Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma
    Mikami, Shuji
    Mizuno, Ryuichi
    Kosaka, Takeo
    Tanaka, Nobuyuki
    Kuroda, Naoto
    Nagashima, Yoji
    Okada, Yasunori
    Oya, Mototsugu
    PATHOLOGY INTERNATIONAL, 2020, 70 (10) : 712 - 723
  • [44] Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma
    Kukko, Heli
    Koljonen, Virve
    Lassus, Patrik
    Tukiainen, Erkki
    Haglund, Caj
    Bohling, Tom
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2587 - 2589
  • [45] Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer
    Kato, Taigo
    Mizuno, Ryuichi
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (05) : 465 - 474
  • [46] Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
    Roskoski, Robert, Jr.
    PHARMACOLOGICAL RESEARCH, 2017, 120 : 116 - 132
  • [47] Expression of insulin-like growth factor I receptor predicts poor survival in patients with clear cell renal cell carcinoma
    Parker, AS
    Cheville, JC
    Lohse, CM
    Weaver, A
    Cerhan, JR
    Blute, ML
    JOURNAL OF UROLOGY, 2003, 169 (04): : 199 - 199
  • [48] Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Wozniak, Antoinette J.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : S1084 - S1085
  • [49] Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies
    Wiele, Andrew J.
    Bathala, Tharakeswara K.
    Hahn, Andrew W.
    Xiao, Lianchun
    Duran, Munevver
    Ross, Jeremy A.
    Jonasch, Eric
    Shah, Amishi Y.
    Campbell, Matthew T.
    Msaouel, Pavlos
    Tannir, Nizar M.
    ONCOLOGIST, 2021, 26 (06): : 476 - 482
  • [50] Efficacy of adjuvant vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (VEGFRi) in renal-cell carcinoma (RCC): Systematic review and meta-analysis
    Botrel, Tobias Engel Ayer
    Paladini, Luciano
    Clark, Otavio
    Clark, Luciana
    Rosa, Bruna Pegoretti
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345